RESUMEN
BACKGROUND:Astragaloside and tanshinone IIa are the effective components of traditional Chinese medicine treatment of myocardial ischemia, and its role in bone marrow mesenchymal stem cel s differentiation into myocardium-like cel s remains unclear. OBJECTIVE:To investigate the effect of tanshinone IIa and astragaloside on the differentiation of bone marrow mesenchymal stem cel s into myocardium-like cel s. METHODS:The maximal non-toxic concentrations of tanshinone IIa and astragaloside were measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, to define the dose of the two in the induced differentiation of bone marrow mesenchymal stem cel s into myocardium-like cel s. The isolated and purified bone marrow mesenchymal stem cel s were divided into five groups:astragaloside group, tanshinone IIa group, astragaloside+tanshinone IIa group, 5-azacitidine group, and blank control group. The expression of gap junction connexin 43 and troponin was determined with enzyme-linked immunosorbent assay. RESULTS AND CONCLUSION:The expression of gap junction connexin 43 and troponin in astragaloside group, tanshinone IIa group, astragaloside+tanshinone IIa group, 5-azacitidine group was higher than that in blank control group (P0.05). A combined use of astragaloside and tanshinone IIa can induce bone marrow mesenchymal stem cel s to differentiate into myocardium-like cel s, and their joint role is better than the role of a single ingredient.
RESUMEN
AIM To observe the changes of plasma neuropeptide Y (NPY) levels in patients with essential hypertension(EH) taking Compound Qishao Jiangya Tablets (Radixet Rhizoma Notoginseng, Radix Paeoniae Alba, Rhizoma Gastrodiae, etc) and to investigate the significance of NPY in the pathogenesis of hypertension and the relationship between NPY and platelet disnormal function. METHODS The plasma NPY concentrations of 60 patients with EH and 20 normal ones were determined by radioimmunoassay, at the same time detected platelet aggregation rate and fibrinogen were detected. RESULTS The levels of plasma NPY in patients with EH were higher than that in normal control group. The NPY levels, the platelet aggregation rate, fibrinogen in the three periods of hypertension (period Ⅰ,Ⅱ, Ⅲ) were all significantly different and were increased with the severity of hypertension. CONCLUSION NPY may participate in the pathophysiological course of hypertension, and the plasma NPY, the platelet aggregation rate of the patients with EH were correlative. The plasma NPY should be dynamscally monitored in order to determine the disease degree. During the treatment for EH attention should be taken to decrease the platelet aggregation rate.